tqb3616 + rifampicin

TQB3616 is a novel, orally administered small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It selectively inhibits CDK4 and CDK6, blocking phosphorylation of the retinoblastoma protein (Rb) early in the G1 phase of the cell cycle. This inhibition prevents progression from G1 to S phase, resulting in cell cycle arrest and suppression of tumor cell proliferation. TQB3616 has demonstrated potent antitumor activity in preclinical models, particularly against hormone receptor-positive breast cancer cells. It shows synergistic effects when combined with endocrine or HER2-targeted therapies. The drug is being developed by Chia Tai Tianqing Pharmaceutical Group for various cancers including breast cancer, liposarcoma, and lung cancer[1][2][5][7]. Rifampicin is a well-known antibiotic primarily used to treat tuberculosis; it acts as an inducer of cytochrome P450 enzymes and can affect the pharmacokinetics of co-administered drugs.